The susceptibility to cytotoxic T lymphocyte mediated lysis of chemically induced sarcomas from immunodeficient and normal mice

Scandinavian Journal of Immunology

Volumn 45, Issue 1, 1997, Pages 28-35

  Svane, I M ^a   Engel, A M ^a   Thomsen, A R ^a   Werdelin, O ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNE DEFICIENCY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SARCOMA;

EID: 0031012247     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-369.x     Document Type: Article

References (40)

1. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
2. Shimizu K, Shen F. Role of different T cell sets in the rejection of syngenic chemically induced tumors. J Immunol 1979;122:1162-5.
3. Barth RJ, Bock SN, Mule JJ, Rosenberg SA. Unique murine tumor associated antigens identified by tumor infiltrating lymphocytes. J Immunol 1990;144:1531-7.
4. Ward PL, Schreiber H. MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light induced tumors. Sem Cancer Biol 1991;2:321-8.
5. Restifo NP, Esquivel F, Asher AL et al. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol 1991;147: 1453-9.
6. Matsumura M, Fremont DH, Peterson PA, Wilson IA. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 1992;257:927-34.
7. Browning M, Bodmer WF. MHC antigens and cancer: implications for T-cell surveillance. Curr Opin Immunol 1992;4:613-18.
8. Wallny H, Deres K, Faath S et al. Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant. Int Immunol 1992;4:1085-90.
9. Christinck ER, Luscher MA, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 1991;352:67-9.
10. Engel A-M, Svane IM, Mouritsen S, Rygaard J, Clausen J, Werdelin O. Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. APMIS, 1996;9:629-39.
11. Svane IM, Engel A-M, Nielsen M, Ljunggren H, Rygaard J, Werdelin O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 1996;26:1844-50.
12. McDougall CJ, Ngoi SS, Goldman I et al. Reduced expression of HLA class I and class II antigens in colon cancer. Cancer Res 1990;50:8023-7.
13. Cromme FV, Airey H, Heemels M-T et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinoma. J Exp Med 1994;179: 335-40.
14. Goodenow R, Vogel MJ, Linsk RL. Histocompatibility antigens on murine tumors. Science 1985;230:777-83.
15. Cohen EP, Kim TS. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Sem Cancer Biol 1994;5:419-28.
16. Petersen BL, Petersen CL, Brændstrup O et al. Expression of beta-2-microglobulin by premalignant epithelium. APMIS 1993;101: 529-36.
17. Hilders CGJM, Houbiers JGA, Krul EJT, Fleuren GJ. The expression of histocompatibility leucocyte antigens in the pathway to cervical carcinoma. Am J Clin Pathol 1994;101:5-12.
18. Garrido F, Carara T, Concha A, Grew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumor development. Immunol Today 1993;14:491-9.
19. Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. Adv Cancer Res 1996;67:155-95.
20. Thomsen AR, Marker O. MHC and non-MHC genes regulate elimination of lymphocytic choriomeningitis virus and antiviral cytotoxic T lymphocyte and delayed-type hypersensitivity mediating T lymphocyte activity in parallel. J Immunol 1989;142: 1333-41.
21. Bartlett GL. Effect of host immunity on the antigenic strength of primary tumors. J Natl Cancer Inst 1972;49:493-504.
22. Randrup Thomsen A, Marker O. Class I gene regulation of haplotype preference may influence antiviral immunity in vivo. Cell Immunol 1989;122:365-76.
23. Welsh RM. Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice. I. Characterization of natural killer cell induction. J Exp Med 1978;148:163-81.
24. Welsh RM. Regulation and role of large granular lymphocytes in arenavirus infections. Curr Top Microbiol Immunol 1987;134: 185-209.
25. Kiessling R, Klein E, Wigzell H. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975;5:112-17.
26. d, and two genes reported to encode tumour-specific antigens. J Exp Med 1988;168:1719-39.
27. d. Transplant Proc 1983;15:2024-5.
28. Allan JE, Doherty PC. Consequences of a single Ir-gene defect for the pathogenesis of lymphocytic choriomeningitis. Immunogenetics 1985;21:581-9.
29. Farrar MA, Schreiber RD. The molecular cell biology of interferon gamma and its receptor. Annu Rev Immunol 1993;11:571-611.
30. Lehmann-Grube F. Lymphocytic choriomeningitis virus. In: Virology Monographs. New York: Springer-Verlag, 1971:16-17.
31. Zinkernagel RM, Pfan CJ, Hengartner H, Althage A. Susceptibility to murine lymphocytic choriomeningitis maps to class I MHC genes-a model for MHC/disease associations. Nature 1985;316: 814-17.
32. Leist T, Althage A, Haenselev E, Hengartner H, Zinkernagel RM. Major histocompatibility complex-linked susceptivity or resistance to disease caused by a non-cytopathic virus varies with the disease parameter evaluated. J Exp Med 1989;170:269-77.
33. Kuroda K, Yamashina K, Kitatani N, Kagishima A, Hamaoka T, Hosaka Y. Characterization of defectiveness in endogenous antigen presentation of novel murine cells established from methylcholantrene-induced fibrosarcomas. Jap J Immunol 1995;84:153-8.
34. Storkus WJ, Dawson JR. Target structures involved in natural killing (NK): characteristics, distribution and candidate molecules. Immunology 1991;10:393-416.
35. Bodmer W. A new look at tumor immunology. Eur J Cancer 1992; 28A:1761-2.
36. Ljunggren H, Kärre K. In search of the missing self: MHC molecules and NK recognition. Immunol Today 1990;11:237-44.
37. Hanna N. The role of natural killer cells, NK cells, in the control of tumor growth and metastasis. Biochimica et Biophysica Acta 1985; 780:213-26.
38. Radzikowski C, Rygaard J, Budzynski W et al. Strain- and age-dependent natural and activated in vitro cytotoxicity in athymic nude mice. APMIS 1994;102:481-8.
39. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon gamma: tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 1986;137:245-54.
40. de Fougerolles AR, Springer TA. Characterization of the function of intercellular adhesion molecule (ICAM-3) 3 and comparison with ICAM-1 and ICAM-2 in immune responses. J Exp Med 1994; 179:619-29.